000153.SZ(000153.SZ)
000153.SZ
Anhui Fengyuan Pharmaceutical Co., Ltd. specializes in the production of generic and specialty pharmaceuticals, primarily in China. The company has a significant presence in the cardiovascular and anti-infective segments, which are critical drivers of its revenue, but it faces challenges due to declining sales and increasing competition.
Anhui Fengyuan generates revenue through the sale of generic and specialty drugs, leveraging its established distribution network across China. The company benefits from cost advantages due to its manufacturing scale and local sourcing of raw materials, although its pricing power is limited in a competitive market.
Changes in regulatory policies affecting drug approvals in China
Market share shifts in the cardiovascular and anti-infective segments
Pricing pressures from competitors in the generic drug market
Fluctuations in raw material costs impacting gross margins
Regulatory changes that could impact drug pricing and approval processes
Technological advancements in drug development that may outpace current capabilities
Intensifying competition from both domestic and international generic manufacturers
Potential for new entrants in the specialty pharmaceutical space
Liquidity concerns due to a current ratio of 0.90, indicating potential short-term financial stress
Negative free cash flow of $0.1B raises concerns about funding for operations and growth
moderate - The pharmaceutical industry tends to be resilient during economic downturns, but demand for non-essential drugs can decline with reduced consumer spending.
Interest rates impact financing costs for capital expenditures and R&D investments, which could affect growth strategies and valuation multiples.
minimal - The company has a manageable debt-to-equity ratio of 0.43, indicating limited reliance on external credit.
value - Investors may be drawn to the stock due to its low price-to-sales ratio of 0.7x, indicating potential undervaluation.
high - The stock has demonstrated significant price fluctuations, evidenced by a 1-year return of -13.0%.